首页|PPP1R14A is Associated with Immunotherapy Resistance in Head and Neck Squamous Cell Carcinoma Identified by Single-Cell and Bulk RNA-Sequencing

PPP1R14A is Associated with Immunotherapy Resistance in Head and Neck Squamous Cell Carcinoma Identified by Single-Cell and Bulk RNA-Sequencing

扫码查看
Objective To identify nivolumab resistance-related genes in patients with head and neck squamous cell carcinoma(HNSCC)using single-cell and bulk RNA-sequencing data.Methods The single-cell and bulk RNA-sequencing data downloaded from the Gene Expression Omnibus database were analyzed to screen out differentially expressed genes(DEGs)between nivolumab resistant and nivolumab sensitive patients using R software.The Least Absolute Shrinkage Selection Operator(LASSO)regression and Recursive Feature Elimination(RFE)algorithm were performed to identify key genes associated with nivolumab resistance.Functional enrichment of DEGs was analyzed with Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses.The relationships of key genes with immune cell infiltration,differentation trajectory,dynamic gene expression profiles,and ligand-receptor interaction were explored.Results We found 83 DEGs.They were mainly enriched in T-cell differentiation,PD-1 and PD-L1 checkpoint,and T-cell receptor pathways.Among six key genes identified using machine learning algorithms,only PPP1R14A gene was differentially expressed between the nivolumab resistant and nivolumab sensitive groups both before and after immunotherapy(P<0.05).The high PPP1R14A gene expression group had lower immune score(P<0.01),higher expression of immunosuppressive factors(such as PDCD1,CTLA4,and PDCD1LG2)(r>0,P<0.05),lower differentiation of infiltrated immune cells(P<0.05),and a higher degree of interaction between HLA and CD4(P<0.05).Conclusions PPP1R14A gene is closely associated with resistance to nivolumab in HNSCC patients.Therefore,PPP1R14A may be a target to ameliorate nivolumab resistance of HNSCC patients.

PPP1R14Ahead and neck squamous cell carcinomaimmunotherapydrug resistance

Jun-Jie Ma、Lei Zhang、Jin Lu、Hao-Xuan Zhang

展开 >

Department of Clinical Medicine,Bengbu Medical University,Bengbu 233030,Anhui,China

Department of General Surgery,The Second Affiliated Hospital of Bengbu Medical University,Bengbu 233030,Anhui,China

Department of Human Anatomy,Bengbu Medical University,Bengbu 233030,Anhui,China

Anhui Key Laboratory of Computa-tional Medicine and Intelligent Health,Bengbu Medical University,Bengbu 233030,Anhui,China

展开 >

National Innovation and Enterpreneurship Training Program for College StudentsKey Laboratory Open Project of Anhui Province

202210367002AHCM2022Z004

2024

中国医学科学杂志(英文版)
中国医学科学院,中国协和医科大学

中国医学科学杂志(英文版)

CSTPCD
影响因子:0.533
ISSN:1001-9294
年,卷(期):2024.39(2)